Siemens Healthineers teams with Novo to expand non-invasive testing access for MASLD and MASH patients

• Siemens Healthineers entered a collaboration with Novo to expand awareness, earlier assessment, non-invasive testing access for MASLD and MASH.
• Partnership targets wider use of blood-based non-invasive tests to reduce reliance on liver biopsy, support earlier triage, improve care pathways.
• Effort highlights Siemens’ Enhanced Liver Fibrosis (ELF) test, a US-authorized blood test for progression risk in advanced fibrosis due to MASH.
• MASLD affects nearly 25% of US adults, remains underdiagnosed, is reversible if caught early, projected costs to exceed USD 635 billion by decade-end.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Siemens Healthineers AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609211045PRIMZONEFULLFEED9830049) on September 21, 2026, and is solely responsible for the information contained therein.